Study of ART0380 in Patients With Biologically Selected Solid Tumors (ARTIST)


Artios Pharma

Status and phase

Phase 2


Metastatic Cancer
Recurrent Endometrial Cancer
Advanced Solid Tumor


Drug: ART0380

Study type


Funder types



2023-504153-12 (EudraCT Number)

Details and patient eligibility


This interventional study will evaluate the efficacy and safety of ART0380 as monotherapy in patients whose tumors have a biology to predict for sensitivity to inhibition of Ataxia-Telangiectasia Mutated and Rad3-related protein kinase (ATR).

Full description

ART0380 is being developed as an oral anti-cancer agent for the treatment of patients with cancers that have defects in deoxyribonucleic acid (DNA) repair.

The study will recruit selected patients with advanced or metastatic solid tumors, specifically:

  • Patients with persistent or recurrent endometrial cancer (EC)
  • Patients with advanced or metastatic solid tumors of any histology

Above patients will be randomized in a 1:1 ratio to one of two dose regimens of ART0380.

Safety will be evaluated on a quarterly basis, at a minimum. Patients may continue to receive ART0380 as long as they are continuing to derive benefit from treatment or until disease progression, withdrawal of consent, or until they experience unacceptable drug-related toxicity.


60 estimated patients




18+ years old


No Healthy Volunteers

Inclusion criteria

  • Patients who have discontinued all previous treatments for cancer for at least 21 days or 5 half-lives (not including palliative radiotherapy at focal sites), whichever is shorter. Palliative radiotherapy must have completed 1 week prior to start of study treatment.
  • Resolution of all toxicities of prior therapy or surgical procedures to baseline or Grade 1 (except for hypothyroidism requiring medication, neuropathy, and alopecia, which must have resolved to Grade ≤2).
  • Have adequate organ function.
  • Patients of childbearing potential and patients with partners of childbearing potential are required to use highly effective contraception.
  • Have an estimated life expectancy of ≥12 weeks, in the judgment of the investigator.
  • Performance status of 0-1 on the Eastern Cooperative Oncology Group scale.
  • Have a non-irradiated tumor tissue sample (archival or newly obtained core biopsy of a tumor lesion) available.

Inclusion Criteria specific to each Arm

Inclusion Criteria for Arm 1 [ART0380 monotherapy (endometrial cancer patients)]

  • Persistent or recurrent EC with biological selection.
  • Patients should have received taxane/platinum chemotherapy unless contraindicated.
  • Measurable disease.

Inclusion Criteria for Arm 2 [ART0380 monotherapy (solid tumors patients)]

  • Advanced or metastatic solid cancers of any histology with biological selection.
  • If a Programmed cell death protein-1 /Programmed death-ligand-1 inhibitor (e.g., pembrolizumab) is approved and available for the patient's cancer, the patient should have received such treatment before participating in this study.
  • Radiologically evaluable disease.

Exclusion criteria

  • Patients who are pregnant.

  • Prior treatment with an inhibitor of ATR, WEE1, checkpoint kinase 1 or PKMYT1.

  • Have a serious concomitant systemic disorder that would compromise the patient's ability to adhere to the protocol.

  • Have ongoing interstitial lung disease or pneumonitis (whether symptomatic or asymptomatic).

  • Patients with treated brain metastases are eligible if follow-up brain imaging after central nervous system (CNS) directed therapy shows no evidence of progression.

  • Have any major gastrointestinal issues that could impact absorption of ART0380.

  • Have a history of allergy or hypersensitivity to study drug components.

  • Have a significant bleeding disorder or vasculitis or had a Grade ≥3 bleeding episode within 12 weeks prior to enrollment.

  • Patients receiving potent inhibitors and inducers of CYP3A4 or CYP3A4 substrates which have a narrow therapeutic range or CYP3A4 sensitive substrates within 2 weeks before the first dose of study treatment will be excluded.

  • Patients receiving the following within 2 weeks of the first dose will be excluded from study treatment.

    1. P-glycoprotein or breast cancer resistance protein (BCRP) inhibitors
    2. Statins
  • Patients who plan to father a child while in the study or within 16 weeks (5 months in France) after the last administration of study treatment.

Trial design

Primary purpose




Interventional model

Parallel Assignment


None (Open label)

60 participants in 2 patient groups

Arm 1 [ART0380 monotherapy (endometrial cancer patients)]
Experimental group
Patients with persistent or recurrent endometrial cancer (EC) will receive ART0380 monotherapy on either a continuous daily dose or on an intermittent schedule for a 21-day cycle.
Drug: ART0380
Arm 2 [ART0380 monotherapy (solid tumors patients)]
Experimental group
Patients with advanced or metastatic solid tumors will receive ART0380 monotherapy on either a continuous daily dose or on an intermittent schedule for a 21-day cycle.
Drug: ART0380

Trial contacts and locations



Central trial contact

Artios Pharma

Data sourced from

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems